nodes	percent_of_prediction	percent_of_DWPC	metapath
Methysergide—SIGMAR1—Tamoxifen—pancreatic cancer	0.373	1	CbGbCtD
Methysergide—HTR7—enteric nervous system—pancreatic cancer	0.0159	0.506	CbGeAlD
Methysergide—HTR2A—enteric nervous system—pancreatic cancer	0.00992	0.316	CbGeAlD
Methysergide—SIGMAR1—islet of Langerhans—pancreatic cancer	0.00178	0.0567	CbGeAlD
Methysergide—SIGMAR1—pancreas—pancreatic cancer	0.00125	0.0398	CbGeAlD
Methysergide—HTR2B—digestive system—pancreatic cancer	0.00107	0.0339	CbGeAlD
Methysergide—Fatigue—Tamoxifen—pancreatic cancer	0.000976	0.00336	CcSEcCtD
Methysergide—Oedema—Sunitinib—pancreatic cancer	0.000969	0.00334	CcSEcCtD
Methysergide—Pain—Tamoxifen—pancreatic cancer	0.000968	0.00334	CcSEcCtD
Methysergide—Constipation—Tamoxifen—pancreatic cancer	0.000968	0.00334	CcSEcCtD
Methysergide—Alopecia—Gemcitabine—pancreatic cancer	0.000967	0.00333	CcSEcCtD
Methysergide—Gastrointestinal disorder—Erlotinib—pancreatic cancer	0.000967	0.00333	CcSEcCtD
Methysergide—Fatigue—Erlotinib—pancreatic cancer	0.000965	0.00333	CcSEcCtD
Methysergide—Pain—Erlotinib—pancreatic cancer	0.000958	0.0033	CcSEcCtD
Methysergide—Constipation—Erlotinib—pancreatic cancer	0.000958	0.0033	CcSEcCtD
Methysergide—Alopecia—Fluorouracil—pancreatic cancer	0.000951	0.00328	CcSEcCtD
Methysergide—Thrombocytopenia—Sunitinib—pancreatic cancer	0.000949	0.00327	CcSEcCtD
Methysergide—Back pain—Irinotecan—pancreatic cancer	0.000946	0.00326	CcSEcCtD
Methysergide—Gastrointestinal pain—Tamoxifen—pancreatic cancer	0.000925	0.00319	CcSEcCtD
Methysergide—Back pain—Gemcitabine—pancreatic cancer	0.000922	0.00318	CcSEcCtD
Methysergide—Gastrointestinal pain—Erlotinib—pancreatic cancer	0.000916	0.00316	CcSEcCtD
Methysergide—HTR7—digestive system—pancreatic cancer	0.000913	0.0291	CbGeAlD
Methysergide—Blood urea increased—Doxorubicin—pancreatic cancer	0.000912	0.00314	CcSEcCtD
Methysergide—Ill-defined disorder—Irinotecan—pancreatic cancer	0.000908	0.00313	CcSEcCtD
Methysergide—Neutropenia—Docetaxel—pancreatic cancer	0.000908	0.00313	CcSEcCtD
Methysergide—Abdominal pain—Tamoxifen—pancreatic cancer	0.000895	0.00308	CcSEcCtD
Methysergide—Body temperature increased—Erlotinib—pancreatic cancer	0.000885	0.00305	CcSEcCtD
Methysergide—Abdominal pain—Erlotinib—pancreatic cancer	0.000885	0.00305	CcSEcCtD
Methysergide—Ill-defined disorder—Gemcitabine—pancreatic cancer	0.000884	0.00305	CcSEcCtD
Methysergide—Weight increased—Docetaxel—pancreatic cancer	0.000883	0.00304	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Sunitinib—pancreatic cancer	0.000883	0.00304	CcSEcCtD
Methysergide—Malaise—Irinotecan—pancreatic cancer	0.000882	0.00304	CcSEcCtD
Methysergide—Weight decreased—Docetaxel—pancreatic cancer	0.000878	0.00303	CcSEcCtD
Methysergide—Insomnia—Sunitinib—pancreatic cancer	0.000877	0.00302	CcSEcCtD
Methysergide—Thrombophlebitis—Epirubicin—pancreatic cancer	0.000875	0.00302	CcSEcCtD
Methysergide—Paraesthesia—Sunitinib—pancreatic cancer	0.00087	0.003	CcSEcCtD
Methysergide—Dyspnoea—Sunitinib—pancreatic cancer	0.000864	0.00298	CcSEcCtD
Methysergide—Malaise—Gemcitabine—pancreatic cancer	0.000859	0.00296	CcSEcCtD
Methysergide—Dyspepsia—Sunitinib—pancreatic cancer	0.000853	0.00294	CcSEcCtD
Methysergide—Gastrointestinal disorder—Sunitinib—pancreatic cancer	0.000837	0.00288	CcSEcCtD
Methysergide—Fatigue—Sunitinib—pancreatic cancer	0.000836	0.00288	CcSEcCtD
Methysergide—Constipation—Sunitinib—pancreatic cancer	0.000829	0.00286	CcSEcCtD
Methysergide—Pain—Sunitinib—pancreatic cancer	0.000829	0.00286	CcSEcCtD
Methysergide—Discomfort—Irinotecan—pancreatic cancer	0.000823	0.00284	CcSEcCtD
Methysergide—Asthenia—Tamoxifen—pancreatic cancer	0.000812	0.0028	CcSEcCtD
Methysergide—Convulsion—Fluorouracil—pancreatic cancer	0.000812	0.0028	CcSEcCtD
Methysergide—Arthralgia—Gemcitabine—pancreatic cancer	0.000811	0.0028	CcSEcCtD
Methysergide—Chest pain—Gemcitabine—pancreatic cancer	0.000811	0.0028	CcSEcCtD
Methysergide—Myalgia—Gemcitabine—pancreatic cancer	0.000811	0.0028	CcSEcCtD
Methysergide—Thrombophlebitis—Doxorubicin—pancreatic cancer	0.00081	0.00279	CcSEcCtD
Methysergide—Asthenia—Erlotinib—pancreatic cancer	0.000803	0.00277	CcSEcCtD
Methysergide—Discomfort—Gemcitabine—pancreatic cancer	0.000802	0.00276	CcSEcCtD
Methysergide—Oedema—Irinotecan—pancreatic cancer	0.000798	0.00275	CcSEcCtD
Methysergide—Myalgia—Fluorouracil—pancreatic cancer	0.000798	0.00275	CcSEcCtD
Methysergide—Chest pain—Fluorouracil—pancreatic cancer	0.000798	0.00275	CcSEcCtD
Methysergide—Gastrointestinal pain—Sunitinib—pancreatic cancer	0.000793	0.00273	CcSEcCtD
Methysergide—Discomfort—Fluorouracil—pancreatic cancer	0.000788	0.00272	CcSEcCtD
Methysergide—Thrombocytopenia—Irinotecan—pancreatic cancer	0.000782	0.00269	CcSEcCtD
Methysergide—Oedema—Gemcitabine—pancreatic cancer	0.000778	0.00268	CcSEcCtD
Methysergide—Diarrhoea—Tamoxifen—pancreatic cancer	0.000774	0.00267	CcSEcCtD
Methysergide—Abdominal pain—Sunitinib—pancreatic cancer	0.000766	0.00264	CcSEcCtD
Methysergide—Body temperature increased—Sunitinib—pancreatic cancer	0.000766	0.00264	CcSEcCtD
Methysergide—Diarrhoea—Erlotinib—pancreatic cancer	0.000766	0.00264	CcSEcCtD
Methysergide—Oedema peripheral—Docetaxel—pancreatic cancer	0.000765	0.00264	CcSEcCtD
Methysergide—Oedema—Fluorouracil—pancreatic cancer	0.000765	0.00264	CcSEcCtD
Methysergide—Thrombocytopenia—Gemcitabine—pancreatic cancer	0.000762	0.00262	CcSEcCtD
Methysergide—Pain in extremity—Epirubicin—pancreatic cancer	0.000758	0.00261	CcSEcCtD
Methysergide—Thrombocytopenia—Fluorouracil—pancreatic cancer	0.000749	0.00258	CcSEcCtD
Methysergide—Dizziness—Tamoxifen—pancreatic cancer	0.000748	0.00258	CcSEcCtD
Methysergide—Tachycardia—Fluorouracil—pancreatic cancer	0.000746	0.00257	CcSEcCtD
Methysergide—Dizziness—Erlotinib—pancreatic cancer	0.00074	0.00255	CcSEcCtD
Methysergide—Insomnia—Irinotecan—pancreatic cancer	0.000722	0.00249	CcSEcCtD
Methysergide—Flushing—Docetaxel—pancreatic cancer	0.000721	0.00249	CcSEcCtD
Methysergide—Vomiting—Tamoxifen—pancreatic cancer	0.00072	0.00248	CcSEcCtD
Methysergide—Paraesthesia—Irinotecan—pancreatic cancer	0.000717	0.00247	CcSEcCtD
Methysergide—Rash—Tamoxifen—pancreatic cancer	0.000714	0.00246	CcSEcCtD
Methysergide—Dermatitis—Tamoxifen—pancreatic cancer	0.000713	0.00246	CcSEcCtD
Methysergide—Ataxia—Epirubicin—pancreatic cancer	0.000712	0.00245	CcSEcCtD
Methysergide—Vomiting—Erlotinib—pancreatic cancer	0.000712	0.00245	CcSEcCtD
Methysergide—Dyspnoea—Irinotecan—pancreatic cancer	0.000712	0.00245	CcSEcCtD
Methysergide—Somnolence—Irinotecan—pancreatic cancer	0.00071	0.00245	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Gemcitabine—pancreatic cancer	0.000709	0.00244	CcSEcCtD
Methysergide—Rash—Erlotinib—pancreatic cancer	0.000706	0.00243	CcSEcCtD
Methysergide—Dermatitis—Erlotinib—pancreatic cancer	0.000705	0.00243	CcSEcCtD
Methysergide—Insomnia—Gemcitabine—pancreatic cancer	0.000704	0.00242	CcSEcCtD
Methysergide—Dyspepsia—Irinotecan—pancreatic cancer	0.000703	0.00242	CcSEcCtD
Methysergide—Pain in extremity—Doxorubicin—pancreatic cancer	0.000701	0.00242	CcSEcCtD
Methysergide—Paraesthesia—Gemcitabine—pancreatic cancer	0.000698	0.00241	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Fluorouracil—pancreatic cancer	0.000697	0.0024	CcSEcCtD
Methysergide—Asthenia—Sunitinib—pancreatic cancer	0.000696	0.0024	CcSEcCtD
Methysergide—Dyspnoea—Gemcitabine—pancreatic cancer	0.000693	0.00239	CcSEcCtD
Methysergide—Orthostatic hypotension—Epirubicin—pancreatic cancer	0.000692	0.00238	CcSEcCtD
Methysergide—Insomnia—Fluorouracil—pancreatic cancer	0.000692	0.00238	CcSEcCtD
Methysergide—Somnolence—Gemcitabine—pancreatic cancer	0.000691	0.00238	CcSEcCtD
Methysergide—Gastrointestinal disorder—Irinotecan—pancreatic cancer	0.000689	0.00238	CcSEcCtD
Methysergide—Fatigue—Irinotecan—pancreatic cancer	0.000688	0.00237	CcSEcCtD
Methysergide—Paraesthesia—Fluorouracil—pancreatic cancer	0.000687	0.00237	CcSEcCtD
Methysergide—Alopecia—Docetaxel—pancreatic cancer	0.000687	0.00237	CcSEcCtD
Methysergide—Pain—Irinotecan—pancreatic cancer	0.000683	0.00235	CcSEcCtD
Methysergide—Constipation—Irinotecan—pancreatic cancer	0.000683	0.00235	CcSEcCtD
Methysergide—Dyspnoea—Fluorouracil—pancreatic cancer	0.000682	0.00235	CcSEcCtD
Methysergide—Somnolence—Fluorouracil—pancreatic cancer	0.00068	0.00234	CcSEcCtD
Methysergide—Dyspepsia—Fluorouracil—pancreatic cancer	0.000673	0.00232	CcSEcCtD
Methysergide—Nausea—Tamoxifen—pancreatic cancer	0.000672	0.00232	CcSEcCtD
Methysergide—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	0.000672	0.00231	CcSEcCtD
Methysergide—Fatigue—Gemcitabine—pancreatic cancer	0.000671	0.00231	CcSEcCtD
Methysergide—Constipation—Gemcitabine—pancreatic cancer	0.000665	0.00229	CcSEcCtD
Methysergide—Pain—Gemcitabine—pancreatic cancer	0.000665	0.00229	CcSEcCtD
Methysergide—Nausea—Erlotinib—pancreatic cancer	0.000665	0.00229	CcSEcCtD
Methysergide—Diarrhoea—Sunitinib—pancreatic cancer	0.000663	0.00229	CcSEcCtD
Methysergide—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	0.00066	0.00228	CcSEcCtD
Methysergide—Ataxia—Doxorubicin—pancreatic cancer	0.000659	0.00227	CcSEcCtD
Methysergide—Feeling abnormal—Irinotecan—pancreatic cancer	0.000658	0.00227	CcSEcCtD
Methysergide—Back pain—Docetaxel—pancreatic cancer	0.000654	0.00225	CcSEcCtD
Methysergide—Pain—Fluorouracil—pancreatic cancer	0.000654	0.00225	CcSEcCtD
Methysergide—Gastrointestinal pain—Irinotecan—pancreatic cancer	0.000653	0.00225	CcSEcCtD
Methysergide—Eosinophilia—Epirubicin—pancreatic cancer	0.000648	0.00223	CcSEcCtD
Methysergide—Dizziness—Sunitinib—pancreatic cancer	0.000641	0.00221	CcSEcCtD
Methysergide—Feeling abnormal—Gemcitabine—pancreatic cancer	0.000641	0.00221	CcSEcCtD
Methysergide—Orthostatic hypotension—Doxorubicin—pancreatic cancer	0.00064	0.00221	CcSEcCtD
Methysergide—Abdominal pain—Irinotecan—pancreatic cancer	0.000631	0.00218	CcSEcCtD
Methysergide—Body temperature increased—Irinotecan—pancreatic cancer	0.000631	0.00218	CcSEcCtD
Methysergide—Feeling abnormal—Fluorouracil—pancreatic cancer	0.00063	0.00217	CcSEcCtD
Methysergide—Vomiting—Sunitinib—pancreatic cancer	0.000616	0.00212	CcSEcCtD
Methysergide—Body temperature increased—Gemcitabine—pancreatic cancer	0.000615	0.00212	CcSEcCtD
Methysergide—Dysuria—Epirubicin—pancreatic cancer	0.000612	0.00211	CcSEcCtD
Methysergide—Neutropenia—Epirubicin—pancreatic cancer	0.000612	0.00211	CcSEcCtD
Methysergide—Rash—Sunitinib—pancreatic cancer	0.000611	0.00211	CcSEcCtD
Methysergide—Dermatitis—Sunitinib—pancreatic cancer	0.000611	0.0021	CcSEcCtD
Methysergide—Body temperature increased—Fluorouracil—pancreatic cancer	0.000605	0.00208	CcSEcCtD
Methysergide—Eosinophilia—Doxorubicin—pancreatic cancer	0.0006	0.00207	CcSEcCtD
Methysergide—Weight increased—Epirubicin—pancreatic cancer	0.000596	0.00205	CcSEcCtD
Methysergide—Weight decreased—Epirubicin—pancreatic cancer	0.000592	0.00204	CcSEcCtD
Methysergide—Convulsion—Docetaxel—pancreatic cancer	0.000586	0.00202	CcSEcCtD
Methysergide—Drowsiness—Epirubicin—pancreatic cancer	0.000584	0.00201	CcSEcCtD
Methysergide—Arthralgia—Docetaxel—pancreatic cancer	0.000576	0.00198	CcSEcCtD
Methysergide—Chest pain—Docetaxel—pancreatic cancer	0.000576	0.00198	CcSEcCtD
Methysergide—Myalgia—Docetaxel—pancreatic cancer	0.000576	0.00198	CcSEcCtD
Methysergide—Nausea—Sunitinib—pancreatic cancer	0.000576	0.00198	CcSEcCtD
Methysergide—Asthenia—Irinotecan—pancreatic cancer	0.000573	0.00197	CcSEcCtD
Methysergide—HTR2A—digestive system—pancreatic cancer	0.000569	0.0181	CbGeAlD
Methysergide—Dysuria—Doxorubicin—pancreatic cancer	0.000566	0.00195	CcSEcCtD
Methysergide—Neutropenia—Doxorubicin—pancreatic cancer	0.000566	0.00195	CcSEcCtD
Methysergide—Asthenia—Gemcitabine—pancreatic cancer	0.000558	0.00192	CcSEcCtD
Methysergide—Oedema—Docetaxel—pancreatic cancer	0.000552	0.0019	CcSEcCtD
Methysergide—Weight increased—Doxorubicin—pancreatic cancer	0.000551	0.0019	CcSEcCtD
Methysergide—Weight decreased—Doxorubicin—pancreatic cancer	0.000548	0.00189	CcSEcCtD
Methysergide—Diarrhoea—Irinotecan—pancreatic cancer	0.000546	0.00188	CcSEcCtD
Methysergide—Thrombocytopenia—Docetaxel—pancreatic cancer	0.00054	0.00186	CcSEcCtD
Methysergide—Drowsiness—Doxorubicin—pancreatic cancer	0.00054	0.00186	CcSEcCtD
Methysergide—Tachycardia—Docetaxel—pancreatic cancer	0.000539	0.00186	CcSEcCtD
Methysergide—Diarrhoea—Gemcitabine—pancreatic cancer	0.000532	0.00183	CcSEcCtD
Methysergide—Dizziness—Irinotecan—pancreatic cancer	0.000528	0.00182	CcSEcCtD
Methysergide—Diarrhoea—Fluorouracil—pancreatic cancer	0.000523	0.0018	CcSEcCtD
Methysergide—Oedema peripheral—Epirubicin—pancreatic cancer	0.000516	0.00178	CcSEcCtD
Methysergide—Vomiting—Irinotecan—pancreatic cancer	0.000508	0.00175	CcSEcCtD
Methysergide—Dizziness—Fluorouracil—pancreatic cancer	0.000506	0.00174	CcSEcCtD
Methysergide—Rash—Irinotecan—pancreatic cancer	0.000503	0.00174	CcSEcCtD
Methysergide—Dermatitis—Irinotecan—pancreatic cancer	0.000503	0.00173	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	0.000503	0.00173	CcSEcCtD
Methysergide—Insomnia—Docetaxel—pancreatic cancer	0.000499	0.00172	CcSEcCtD
Methysergide—Paraesthesia—Docetaxel—pancreatic cancer	0.000496	0.00171	CcSEcCtD
Methysergide—Vomiting—Gemcitabine—pancreatic cancer	0.000495	0.0017	CcSEcCtD
Methysergide—Dyspnoea—Docetaxel—pancreatic cancer	0.000492	0.0017	CcSEcCtD
Methysergide—Somnolence—Docetaxel—pancreatic cancer	0.000491	0.00169	CcSEcCtD
Methysergide—Rash—Gemcitabine—pancreatic cancer	0.00049	0.00169	CcSEcCtD
Methysergide—Dermatitis—Gemcitabine—pancreatic cancer	0.00049	0.00169	CcSEcCtD
Methysergide—Flushing—Epirubicin—pancreatic cancer	0.000486	0.00168	CcSEcCtD
Methysergide—Vomiting—Fluorouracil—pancreatic cancer	0.000486	0.00168	CcSEcCtD
Methysergide—Dyspepsia—Docetaxel—pancreatic cancer	0.000486	0.00167	CcSEcCtD
Methysergide—Rash—Fluorouracil—pancreatic cancer	0.000482	0.00166	CcSEcCtD
Methysergide—Dermatitis—Fluorouracil—pancreatic cancer	0.000482	0.00166	CcSEcCtD
Methysergide—Oedema peripheral—Doxorubicin—pancreatic cancer	0.000478	0.00165	CcSEcCtD
Methysergide—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.000477	0.00164	CcSEcCtD
Methysergide—Fatigue—Docetaxel—pancreatic cancer	0.000476	0.00164	CcSEcCtD
Methysergide—Nausea—Irinotecan—pancreatic cancer	0.000474	0.00163	CcSEcCtD
Methysergide—Constipation—Docetaxel—pancreatic cancer	0.000472	0.00163	CcSEcCtD
Methysergide—Pain—Docetaxel—pancreatic cancer	0.000472	0.00163	CcSEcCtD
Methysergide—Alopecia—Epirubicin—pancreatic cancer	0.000463	0.0016	CcSEcCtD
Methysergide—Nausea—Gemcitabine—pancreatic cancer	0.000462	0.00159	CcSEcCtD
Methysergide—Feeling abnormal—Docetaxel—pancreatic cancer	0.000455	0.00157	CcSEcCtD
Methysergide—Nausea—Fluorouracil—pancreatic cancer	0.000454	0.00157	CcSEcCtD
Methysergide—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.000451	0.00156	CcSEcCtD
Methysergide—Flushing—Doxorubicin—pancreatic cancer	0.00045	0.00155	CcSEcCtD
Methysergide—Back pain—Epirubicin—pancreatic cancer	0.000441	0.00152	CcSEcCtD
Methysergide—Abdominal pain—Docetaxel—pancreatic cancer	0.000436	0.0015	CcSEcCtD
Methysergide—Body temperature increased—Docetaxel—pancreatic cancer	0.000436	0.0015	CcSEcCtD
Methysergide—Alopecia—Doxorubicin—pancreatic cancer	0.000428	0.00148	CcSEcCtD
Methysergide—Ill-defined disorder—Epirubicin—pancreatic cancer	0.000423	0.00146	CcSEcCtD
Methysergide—Malaise—Epirubicin—pancreatic cancer	0.000411	0.00142	CcSEcCtD
Methysergide—Back pain—Doxorubicin—pancreatic cancer	0.000408	0.00141	CcSEcCtD
Methysergide—Asthenia—Docetaxel—pancreatic cancer	0.000396	0.00136	CcSEcCtD
Methysergide—Convulsion—Epirubicin—pancreatic cancer	0.000395	0.00136	CcSEcCtD
Methysergide—Ill-defined disorder—Doxorubicin—pancreatic cancer	0.000392	0.00135	CcSEcCtD
Methysergide—Arthralgia—Epirubicin—pancreatic cancer	0.000388	0.00134	CcSEcCtD
Methysergide—Chest pain—Epirubicin—pancreatic cancer	0.000388	0.00134	CcSEcCtD
Methysergide—Myalgia—Epirubicin—pancreatic cancer	0.000388	0.00134	CcSEcCtD
Methysergide—Discomfort—Epirubicin—pancreatic cancer	0.000384	0.00132	CcSEcCtD
Methysergide—Malaise—Doxorubicin—pancreatic cancer	0.000381	0.00131	CcSEcCtD
Methysergide—Diarrhoea—Docetaxel—pancreatic cancer	0.000378	0.0013	CcSEcCtD
Methysergide—Oedema—Epirubicin—pancreatic cancer	0.000372	0.00128	CcSEcCtD
Methysergide—Convulsion—Doxorubicin—pancreatic cancer	0.000366	0.00126	CcSEcCtD
Methysergide—Dizziness—Docetaxel—pancreatic cancer	0.000365	0.00126	CcSEcCtD
Methysergide—Thrombocytopenia—Epirubicin—pancreatic cancer	0.000365	0.00126	CcSEcCtD
Methysergide—Tachycardia—Epirubicin—pancreatic cancer	0.000363	0.00125	CcSEcCtD
Methysergide—Arthralgia—Doxorubicin—pancreatic cancer	0.000359	0.00124	CcSEcCtD
Methysergide—Chest pain—Doxorubicin—pancreatic cancer	0.000359	0.00124	CcSEcCtD
Methysergide—Myalgia—Doxorubicin—pancreatic cancer	0.000359	0.00124	CcSEcCtD
Methysergide—Discomfort—Doxorubicin—pancreatic cancer	0.000355	0.00122	CcSEcCtD
Methysergide—Vomiting—Docetaxel—pancreatic cancer	0.000351	0.00121	CcSEcCtD
Methysergide—Rash—Docetaxel—pancreatic cancer	0.000348	0.0012	CcSEcCtD
Methysergide—Dermatitis—Docetaxel—pancreatic cancer	0.000348	0.0012	CcSEcCtD
Methysergide—Oedema—Doxorubicin—pancreatic cancer	0.000344	0.00119	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	0.000339	0.00117	CcSEcCtD
Methysergide—Thrombocytopenia—Doxorubicin—pancreatic cancer	0.000337	0.00116	CcSEcCtD
Methysergide—Insomnia—Epirubicin—pancreatic cancer	0.000337	0.00116	CcSEcCtD
Methysergide—Tachycardia—Doxorubicin—pancreatic cancer	0.000336	0.00116	CcSEcCtD
Methysergide—Paraesthesia—Epirubicin—pancreatic cancer	0.000334	0.00115	CcSEcCtD
Methysergide—Dyspnoea—Epirubicin—pancreatic cancer	0.000332	0.00114	CcSEcCtD
Methysergide—Somnolence—Epirubicin—pancreatic cancer	0.000331	0.00114	CcSEcCtD
Methysergide—Nausea—Docetaxel—pancreatic cancer	0.000328	0.00113	CcSEcCtD
Methysergide—Dyspepsia—Epirubicin—pancreatic cancer	0.000328	0.00113	CcSEcCtD
Methysergide—Gastrointestinal disorder—Epirubicin—pancreatic cancer	0.000321	0.00111	CcSEcCtD
Methysergide—Fatigue—Epirubicin—pancreatic cancer	0.000321	0.00111	CcSEcCtD
Methysergide—Constipation—Epirubicin—pancreatic cancer	0.000318	0.0011	CcSEcCtD
Methysergide—Pain—Epirubicin—pancreatic cancer	0.000318	0.0011	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	0.000314	0.00108	CcSEcCtD
Methysergide—Insomnia—Doxorubicin—pancreatic cancer	0.000312	0.00107	CcSEcCtD
Methysergide—Paraesthesia—Doxorubicin—pancreatic cancer	0.000309	0.00107	CcSEcCtD
Methysergide—Dyspnoea—Doxorubicin—pancreatic cancer	0.000307	0.00106	CcSEcCtD
Methysergide—Feeling abnormal—Epirubicin—pancreatic cancer	0.000307	0.00106	CcSEcCtD
Methysergide—Somnolence—Doxorubicin—pancreatic cancer	0.000306	0.00106	CcSEcCtD
Methysergide—Gastrointestinal pain—Epirubicin—pancreatic cancer	0.000304	0.00105	CcSEcCtD
Methysergide—Dyspepsia—Doxorubicin—pancreatic cancer	0.000303	0.00105	CcSEcCtD
Methysergide—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	0.000297	0.00102	CcSEcCtD
Methysergide—Fatigue—Doxorubicin—pancreatic cancer	0.000297	0.00102	CcSEcCtD
Methysergide—Pain—Doxorubicin—pancreatic cancer	0.000295	0.00102	CcSEcCtD
Methysergide—Constipation—Doxorubicin—pancreatic cancer	0.000295	0.00102	CcSEcCtD
Methysergide—Abdominal pain—Epirubicin—pancreatic cancer	0.000294	0.00101	CcSEcCtD
Methysergide—Body temperature increased—Epirubicin—pancreatic cancer	0.000294	0.00101	CcSEcCtD
Methysergide—Feeling abnormal—Doxorubicin—pancreatic cancer	0.000284	0.000978	CcSEcCtD
Methysergide—Gastrointestinal pain—Doxorubicin—pancreatic cancer	0.000282	0.000971	CcSEcCtD
Methysergide—Abdominal pain—Doxorubicin—pancreatic cancer	0.000272	0.000939	CcSEcCtD
Methysergide—Body temperature increased—Doxorubicin—pancreatic cancer	0.000272	0.000939	CcSEcCtD
Methysergide—Asthenia—Epirubicin—pancreatic cancer	0.000267	0.000921	CcSEcCtD
Methysergide—Diarrhoea—Epirubicin—pancreatic cancer	0.000255	0.000878	CcSEcCtD
Methysergide—Asthenia—Doxorubicin—pancreatic cancer	0.000247	0.000852	CcSEcCtD
Methysergide—Dizziness—Epirubicin—pancreatic cancer	0.000246	0.000849	CcSEcCtD
Methysergide—Vomiting—Epirubicin—pancreatic cancer	0.000237	0.000816	CcSEcCtD
Methysergide—Diarrhoea—Doxorubicin—pancreatic cancer	0.000236	0.000812	CcSEcCtD
Methysergide—Rash—Epirubicin—pancreatic cancer	0.000235	0.000809	CcSEcCtD
Methysergide—Dermatitis—Epirubicin—pancreatic cancer	0.000235	0.000808	CcSEcCtD
Methysergide—Dizziness—Doxorubicin—pancreatic cancer	0.000228	0.000785	CcSEcCtD
Methysergide—Nausea—Epirubicin—pancreatic cancer	0.000221	0.000762	CcSEcCtD
Methysergide—Vomiting—Doxorubicin—pancreatic cancer	0.000219	0.000755	CcSEcCtD
Methysergide—Rash—Doxorubicin—pancreatic cancer	0.000217	0.000749	CcSEcCtD
Methysergide—Dermatitis—Doxorubicin—pancreatic cancer	0.000217	0.000748	CcSEcCtD
Methysergide—Nausea—Doxorubicin—pancreatic cancer	0.000205	0.000705	CcSEcCtD
Methysergide—HTR1B—Signaling Pathways—PIK3CD—pancreatic cancer	2.71e-05	8.88e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling by GPCR—KRAS—pancreatic cancer	2.71e-05	8.87e-05	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—MYC—pancreatic cancer	2.71e-05	8.87e-05	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—TGFB1—pancreatic cancer	2.7e-05	8.85e-05	CbGpPWpGaD
Methysergide—HTR1B—GPCR downstream signaling—PIK3CA—pancreatic cancer	2.69e-05	8.79e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—HIF1A—pancreatic cancer	2.67e-05	8.73e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—TSC2—pancreatic cancer	2.66e-05	8.71e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling by GPCR—KRAS—pancreatic cancer	2.65e-05	8.69e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—HIF1A—pancreatic cancer	2.65e-05	8.68e-05	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—EGFR—pancreatic cancer	2.65e-05	8.68e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—TSC2—pancreatic cancer	2.65e-05	8.66e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling by GPCR—EGFR—pancreatic cancer	2.64e-05	8.64e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—PIK3CB—pancreatic cancer	2.63e-05	8.62e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—APOE—pancreatic cancer	2.6e-05	8.52e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—APOE—pancreatic cancer	2.59e-05	8.48e-05	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—MYC—pancreatic cancer	2.56e-05	8.37e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—KDR—pancreatic cancer	2.55e-05	8.35e-05	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—TGFB1—pancreatic cancer	2.55e-05	8.35e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—PIK3CD—pancreatic cancer	2.55e-05	8.34e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—KDR—pancreatic cancer	2.54e-05	8.31e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—CXCL8—pancreatic cancer	2.53e-05	8.28e-05	CbGpPWpGaD
Methysergide—HTR2B—GPCR downstream signaling—PIK3CA—pancreatic cancer	2.52e-05	8.26e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling by GPCR—PIK3CA—pancreatic cancer	2.51e-05	8.22e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling by GPCR—PIK3CA—pancreatic cancer	2.51e-05	8.21e-05	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—KRAS—pancreatic cancer	2.5e-05	8.2e-05	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—EGFR—pancreatic cancer	2.5e-05	8.19e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling by GPCR—KRAS—pancreatic cancer	2.49e-05	8.16e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling by GPCR—PIK3CA—pancreatic cancer	2.49e-05	8.15e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling by GPCR—PIK3CA—pancreatic cancer	2.44e-05	7.98e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—PIK3CB—pancreatic cancer	2.43e-05	7.96e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—PIK3CB—pancreatic cancer	2.43e-05	7.95e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—NFKBIA—pancreatic cancer	2.43e-05	7.94e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—PIK3CB—pancreatic cancer	2.41e-05	7.9e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—NFKBIA—pancreatic cancer	2.41e-05	7.9e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—TERT—pancreatic cancer	2.41e-05	7.89e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—NOTCH1—pancreatic cancer	2.4e-05	7.86e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—NOTCH1—pancreatic cancer	2.39e-05	7.82e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—PIK3CB—pancreatic cancer	2.36e-05	7.74e-05	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—KRAS—pancreatic cancer	2.36e-05	7.73e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—PIK3CG—pancreatic cancer	2.35e-05	7.69e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—NRAS—pancreatic cancer	2.35e-05	7.69e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—PIK3CG—pancreatic cancer	2.34e-05	7.65e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—NRAS—pancreatic cancer	2.34e-05	7.65e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—CXCL8—pancreatic cancer	2.34e-05	7.65e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—CXCL8—pancreatic cancer	2.33e-05	7.64e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—EGF—pancreatic cancer	2.32e-05	7.6e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling by GPCR—HRAS—pancreatic cancer	2.32e-05	7.6e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling by GPCR—HRAS—pancreatic cancer	2.32e-05	7.59e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—CXCL8—pancreatic cancer	2.32e-05	7.59e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—EGF—pancreatic cancer	2.31e-05	7.56e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling by GPCR—HRAS—pancreatic cancer	2.3e-05	7.54e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—HIF1A—pancreatic cancer	2.3e-05	7.54e-05	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—PIK3CA—pancreatic cancer	2.3e-05	7.53e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—TSC2—pancreatic cancer	2.3e-05	7.52e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling by GPCR—PIK3CA—pancreatic cancer	2.29e-05	7.5e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—CXCL8—pancreatic cancer	2.27e-05	7.43e-05	CbGpPWpGaD
Methysergide—HTR6—GPCR downstream signaling—AKT1—pancreatic cancer	2.26e-05	7.39e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling by GPCR—HRAS—pancreatic cancer	2.26e-05	7.39e-05	CbGpPWpGaD
Methysergide—HTR7—GPCR downstream signaling—AKT1—pancreatic cancer	2.26e-05	7.38e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—APOE—pancreatic cancer	2.25e-05	7.36e-05	CbGpPWpGaD
Methysergide—HTR1D—GPCR downstream signaling—AKT1—pancreatic cancer	2.24e-05	7.33e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—CASP3—pancreatic cancer	2.24e-05	7.32e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—CASP3—pancreatic cancer	2.23e-05	7.31e-05	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—TP53—pancreatic cancer	2.23e-05	7.29e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—PIK3CB—pancreatic cancer	2.22e-05	7.27e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—CASP3—pancreatic cancer	2.22e-05	7.27e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—KDR—pancreatic cancer	2.2e-05	7.21e-05	CbGpPWpGaD
Methysergide—HTR1B—GPCR downstream signaling—AKT1—pancreatic cancer	2.19e-05	7.18e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—CCND1—pancreatic cancer	2.18e-05	7.13e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—CCND1—pancreatic cancer	2.17e-05	7.12e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—CASP3—pancreatic cancer	2.17e-05	7.12e-05	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—PIK3CA—pancreatic cancer	2.17e-05	7.1e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—CCND1—pancreatic cancer	2.16e-05	7.07e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—CTNNB1—pancreatic cancer	2.16e-05	7.06e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—CTNNB1—pancreatic cancer	2.15e-05	7.05e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—EGFR—pancreatic cancer	2.14e-05	7.01e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—CTNNB1—pancreatic cancer	2.14e-05	7e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—CXCL8—pancreatic cancer	2.13e-05	6.98e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—EGFR—pancreatic cancer	2.13e-05	6.97e-05	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—HRAS—pancreatic cancer	2.13e-05	6.97e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling by GPCR—HRAS—pancreatic cancer	2.12e-05	6.94e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—CCND1—pancreatic cancer	2.12e-05	6.93e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—MMP9—pancreatic cancer	2.11e-05	6.92e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—MMP9—pancreatic cancer	2.11e-05	6.91e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—PTEN—pancreatic cancer	2.1e-05	6.88e-05	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—TP53—pancreatic cancer	2.1e-05	6.87e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—PTEN—pancreatic cancer	2.1e-05	6.87e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—MMP9—pancreatic cancer	2.1e-05	6.87e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—NFKBIA—pancreatic cancer	2.1e-05	6.86e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—CTNNB1—pancreatic cancer	2.1e-05	6.86e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—PTEN—pancreatic cancer	2.09e-05	6.83e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—NOTCH1—pancreatic cancer	2.08e-05	6.79e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—PIK3CD—pancreatic cancer	2.07e-05	6.76e-05	CbGpPWpGaD
Methysergide—HTR2B—GPCR downstream signaling—AKT1—pancreatic cancer	2.06e-05	6.75e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—PIK3CD—pancreatic cancer	2.05e-05	6.73e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—MMP9—pancreatic cancer	2.05e-05	6.72e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling by GPCR—AKT1—pancreatic cancer	2.05e-05	6.71e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling by GPCR—AKT1—pancreatic cancer	2.05e-05	6.7e-05	CbGpPWpGaD
Methysergide—HTR1A—GPCR downstream signaling—PIK3CA—pancreatic cancer	2.05e-05	6.7e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—PTEN—pancreatic cancer	2.04e-05	6.68e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—CASP3—pancreatic cancer	2.04e-05	6.68e-05	CbGpPWpGaD
Methysergide—HTR2C—GPCR downstream signaling—PIK3CA—pancreatic cancer	2.04e-05	6.66e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling by GPCR—AKT1—pancreatic cancer	2.03e-05	6.66e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—PIK3CG—pancreatic cancer	2.03e-05	6.64e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—NRAS—pancreatic cancer	2.03e-05	6.64e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—KRAS—pancreatic cancer	2.02e-05	6.62e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—KRAS—pancreatic cancer	2.01e-05	6.59e-05	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—HRAS—pancreatic cancer	2.01e-05	6.57e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—EGF—pancreatic cancer	2.01e-05	6.57e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling by GPCR—AKT1—pancreatic cancer	1.99e-05	6.52e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—CCND1—pancreatic cancer	1.99e-05	6.51e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—CTNNB1—pancreatic cancer	1.97e-05	6.44e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—SRC—pancreatic cancer	1.95e-05	6.38e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—SRC—pancreatic cancer	1.95e-05	6.37e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—SRC—pancreatic cancer	1.93e-05	6.33e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—MMP9—pancreatic cancer	1.93e-05	6.32e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—PTEN—pancreatic cancer	1.92e-05	6.28e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—VEGFA—pancreatic cancer	1.9e-05	6.21e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—VEGFA—pancreatic cancer	1.9e-05	6.21e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—SRC—pancreatic cancer	1.89e-05	6.2e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—VEGFA—pancreatic cancer	1.88e-05	6.17e-05	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—AKT1—pancreatic cancer	1.88e-05	6.15e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—STAT3—pancreatic cancer	1.88e-05	6.15e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—STAT3—pancreatic cancer	1.88e-05	6.15e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—NRAS—pancreatic cancer	1.87e-05	6.14e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—NRAS—pancreatic cancer	1.87e-05	6.13e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling by GPCR—AKT1—pancreatic cancer	1.87e-05	6.13e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—STAT3—pancreatic cancer	1.87e-05	6.11e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—NRAS—pancreatic cancer	1.86e-05	6.09e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—PIK3CA—pancreatic cancer	1.86e-05	6.08e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—EGFR—pancreatic cancer	1.85e-05	6.05e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—PIK3CA—pancreatic cancer	1.85e-05	6.05e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—VEGFA—pancreatic cancer	1.84e-05	6.04e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—STAT3—pancreatic cancer	1.83e-05	5.98e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—NRAS—pancreatic cancer	1.82e-05	5.96e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—PIK3CB—pancreatic cancer	1.8e-05	5.89e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—PIK3CB—pancreatic cancer	1.79e-05	5.86e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—PIK3CD—pancreatic cancer	1.78e-05	5.84e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—SRC—pancreatic cancer	1.78e-05	5.82e-05	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—AKT1—pancreatic cancer	1.77e-05	5.8e-05	CbGpPWpGaD
Methysergide—HTR2A—GPCR downstream signaling—PIK3CA—pancreatic cancer	1.77e-05	5.79e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—KRAS—pancreatic cancer	1.75e-05	5.72e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—MYC—pancreatic cancer	1.75e-05	5.72e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—MYC—pancreatic cancer	1.74e-05	5.71e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—TGFB1—pancreatic cancer	1.74e-05	5.7e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—TGFB1—pancreatic cancer	1.74e-05	5.7e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—MYC—pancreatic cancer	1.73e-05	5.67e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—VEGFA—pancreatic cancer	1.73e-05	5.67e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—CXCL8—pancreatic cancer	1.73e-05	5.66e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—TGFB1—pancreatic cancer	1.73e-05	5.66e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—CXCL8—pancreatic cancer	1.72e-05	5.63e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—HRAS—pancreatic cancer	1.72e-05	5.63e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—STAT3—pancreatic cancer	1.72e-05	5.62e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—NRAS—pancreatic cancer	1.71e-05	5.6e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—HRAS—pancreatic cancer	1.71e-05	5.6e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—EGFR—pancreatic cancer	1.71e-05	5.59e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—EGFR—pancreatic cancer	1.71e-05	5.59e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—MYC—pancreatic cancer	1.7e-05	5.56e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—EGFR—pancreatic cancer	1.7e-05	5.55e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—TGFB1—pancreatic cancer	1.69e-05	5.54e-05	CbGpPWpGaD
Methysergide—HTR1A—GPCR downstream signaling—AKT1—pancreatic cancer	1.67e-05	5.47e-05	CbGpPWpGaD
Methysergide—HTR2C—GPCR downstream signaling—AKT1—pancreatic cancer	1.66e-05	5.44e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—EGFR—pancreatic cancer	1.66e-05	5.43e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—CASP3—pancreatic cancer	1.66e-05	5.42e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—CASP3—pancreatic cancer	1.65e-05	5.39e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—KRAS—pancreatic cancer	1.61e-05	5.28e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—KRAS—pancreatic cancer	1.61e-05	5.28e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—CCND1—pancreatic cancer	1.61e-05	5.28e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—PIK3CA—pancreatic cancer	1.6e-05	5.25e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—CCND1—pancreatic cancer	1.6e-05	5.25e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—KRAS—pancreatic cancer	1.6e-05	5.24e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—CTNNB1—pancreatic cancer	1.6e-05	5.22e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—MYC—pancreatic cancer	1.59e-05	5.22e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—TGFB1—pancreatic cancer	1.59e-05	5.21e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—CTNNB1—pancreatic cancer	1.59e-05	5.2e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—KRAS—pancreatic cancer	1.57e-05	5.13e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—MMP9—pancreatic cancer	1.56e-05	5.12e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—EGFR—pancreatic cancer	1.56e-05	5.1e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—MMP9—pancreatic cancer	1.56e-05	5.1e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—PTEN—pancreatic cancer	1.56e-05	5.09e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—PIK3CB—pancreatic cancer	1.56e-05	5.09e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—PTEN—pancreatic cancer	1.55e-05	5.07e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—AKT1—pancreatic cancer	1.52e-05	4.97e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—AKT1—pancreatic cancer	1.51e-05	4.94e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—CXCL8—pancreatic cancer	1.49e-05	4.89e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—HRAS—pancreatic cancer	1.48e-05	4.86e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—PIK3CA—pancreatic cancer	1.48e-05	4.85e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—PIK3CA—pancreatic cancer	1.48e-05	4.85e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—KRAS—pancreatic cancer	1.47e-05	4.82e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—PIK3CA—pancreatic cancer	1.47e-05	4.82e-05	CbGpPWpGaD
Methysergide—HTR2A—GPCR downstream signaling—AKT1—pancreatic cancer	1.44e-05	4.73e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—SRC—pancreatic cancer	1.44e-05	4.72e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—PIK3CA—pancreatic cancer	1.44e-05	4.72e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—SRC—pancreatic cancer	1.44e-05	4.7e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—TP53—pancreatic cancer	1.43e-05	4.69e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—TP53—pancreatic cancer	1.43e-05	4.69e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—CASP3—pancreatic cancer	1.43e-05	4.68e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—TP53—pancreatic cancer	1.42e-05	4.66e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—VEGFA—pancreatic cancer	1.41e-05	4.6e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—VEGFA—pancreatic cancer	1.4e-05	4.58e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—TP53—pancreatic cancer	1.39e-05	4.56e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—CCND1—pancreatic cancer	1.39e-05	4.56e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—STAT3—pancreatic cancer	1.39e-05	4.55e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—NRAS—pancreatic cancer	1.39e-05	4.54e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—STAT3—pancreatic cancer	1.38e-05	4.53e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—NRAS—pancreatic cancer	1.38e-05	4.52e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—CTNNB1—pancreatic cancer	1.38e-05	4.51e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—HRAS—pancreatic cancer	1.37e-05	4.49e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—HRAS—pancreatic cancer	1.37e-05	4.49e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—HRAS—pancreatic cancer	1.36e-05	4.46e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—PIK3CA—pancreatic cancer	1.35e-05	4.43e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—MMP9—pancreatic cancer	1.35e-05	4.43e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—PTEN—pancreatic cancer	1.34e-05	4.4e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—HRAS—pancreatic cancer	1.33e-05	4.36e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—AKT1—pancreatic cancer	1.31e-05	4.29e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—TP53—pancreatic cancer	1.31e-05	4.29e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—MYC—pancreatic cancer	1.29e-05	4.23e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—TGFB1—pancreatic cancer	1.29e-05	4.22e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—MYC—pancreatic cancer	1.29e-05	4.21e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—TGFB1—pancreatic cancer	1.28e-05	4.2e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—EGFR—pancreatic cancer	1.26e-05	4.14e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—EGFR—pancreatic cancer	1.26e-05	4.12e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—HRAS—pancreatic cancer	1.25e-05	4.1e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—SRC—pancreatic cancer	1.25e-05	4.08e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—VEGFA—pancreatic cancer	1.21e-05	3.97e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—AKT1—pancreatic cancer	1.21e-05	3.96e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—AKT1—pancreatic cancer	1.21e-05	3.96e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—AKT1—pancreatic cancer	1.2e-05	3.93e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—STAT3—pancreatic cancer	1.2e-05	3.93e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—NRAS—pancreatic cancer	1.2e-05	3.92e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—KRAS—pancreatic cancer	1.19e-05	3.91e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—KRAS—pancreatic cancer	1.19e-05	3.89e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—AKT1—pancreatic cancer	1.18e-05	3.85e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—MYC—pancreatic cancer	1.12e-05	3.66e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—TGFB1—pancreatic cancer	1.11e-05	3.65e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—AKT1—pancreatic cancer	1.11e-05	3.62e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—PIK3CA—pancreatic cancer	1.1e-05	3.59e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—EGFR—pancreatic cancer	1.09e-05	3.58e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—PIK3CA—pancreatic cancer	1.09e-05	3.57e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—TP53—pancreatic cancer	1.06e-05	3.48e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—TP53—pancreatic cancer	1.06e-05	3.46e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—KRAS—pancreatic cancer	1.03e-05	3.38e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—HRAS—pancreatic cancer	1.02e-05	3.32e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—HRAS—pancreatic cancer	1.01e-05	3.31e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—PIK3CA—pancreatic cancer	9.48e-06	3.1e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—TP53—pancreatic cancer	9.17e-06	3e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—AKT1—pancreatic cancer	8.97e-06	2.93e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—AKT1—pancreatic cancer	8.92e-06	2.92e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—HRAS—pancreatic cancer	8.77e-06	2.87e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—AKT1—pancreatic cancer	7.75e-06	2.54e-05	CbGpPWpGaD
